A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In vivo models were used to evaluate the compound 19r for antidepressive, anxiolytic, and analgesic activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2010.07.021 | DOI Listing |
Publication Analysis
Top Keywords
synthesis pharmacological
4
pharmacological evaluation
4
evaluation 3-aryl-3-azolylpropan-1-amines
4
3-aryl-3-azolylpropan-1-amines selective
4
selective triple
4
triple serotonin/norepinephrine/dopamine
4
serotonin/norepinephrine/dopamine reuptake
4
reuptake inhibitors
4
inhibitors series
4
series 3-aryl-3-azolylpropan-1-amines
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!